Healthcare Industry News: Bristol-Myers Squibb
News Release - April 17, 2009
Lilly Names Susan Mahony Senior Vice President of Human ResourcesINDIANAPOLIS, April 17 (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY ) today announced that Sue Mahony, Ph. D., general manager of Lilly's Canadian affiliate, will join Lilly's senior management team as the new senior vice president of human resources beginning May 1. She succeeds Tony Murphy, Ph. D, who announced his retirement last month.
Mahony joined Lilly more than eight years ago, after more than a decade in sales and marketing roles in the United Kingdom and Europe for Amgen, Bristol-Myers Squibb, and Schering-Plough. She was named general manager of Lilly Canada in 2008 after roles in global marketing and new product development, including a leadership role in the development of Cymbaltaź. Mahony was also the Six Sigma leader for Lilly's sales and marketing component.
"Every facet of our business is directly influenced by the way we hire, develop, motivate, and engage our employees," said Lilly Chairman, President and CEO John Lechleiter, Ph. D. "Sue brings a fresh perspective that will help guide the way we anticipate and respond to a rapidly changing environment. Her prior experiences, coupled with her record of strong leadership, will enable Lilly to sustain a strong human resources function and ensure that we are able to compete and win in the face of unprecedented challenge and opportunity."
Mahony received her bachelor's degree and Ph. D. in pharmacy from Aston University in Great Britain, and holds an MBA from the London Business School.
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.
Source: Eli Lilly
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsFDA Approves Verzenio(R) (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer
OLUMIANT(R) Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata
Lilly Announces Leadership Changes and Formation of Neuroscience and Immunology Business Units